Bloomberg -- GlaxoSmithKline Plc’s experimental malaria vaccine, already shown to cut the risk of children contracting the disease by half after 8 months, was equally effective after 15, a study showed.
Bloomberg -- GlaxoSmithKline Plc’s experimental malaria vaccine, already shown to cut the risk of children contracting the disease by half after 8 months, was equally effective after 15, a study showed.
